Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
2015 Jan
Journal Article
Authors:
Howard, A.;
Fernandez-Vina, M.A.;
Appelbaum, F.R.;
Confer, D.L.;
Devine, S.M.;
Horowitz, M.M.;
Mendizabal, A.;
Laport, G.G.;
Pasquini, M.C.;
Spellman, S.R.
Secondary:
Biol Blood Marrow Transplant
Volume:
21
Pagination:
4-7
Issue:
1
PMID:
25278457
DOI:
10.1016/j.bbmt.2014.09.017
Keywords:
Bone Marrow Transplantation; Clinical Trials as Topic; Consensus; Cord Blood Stem Cell Transplantation; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Tissue Donors; Transplantation, Homologous
Abstract:
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts large, multi-institutional clinical trials with the goal of improving the outcomes of hematopoietic cell transplantation (HCT) for patients with life-threatening disorders. Well-designed HCT trials benefit from standardized criteria for defining diagnoses, treatment plans, and graft source selection. In this perspective, we summarize evidence supporting criteria for the selection of related and unrelated adult volunteer progenitor cell donors or umbilical cord blood units. These standardized criteria for graft source selection have been adopted by the BMT CTN to enhance the interpretation of clinical findings within and among future clinical protocols.
